key: cord-1033375-ehxxvenb authors: Pang, Xiaocong; Cui, Yimin; Zhu, Yizhun title: Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication date: 2020-06-24 journal: Acta Pharmacol Sin DOI: 10.1038/s41401-020-0430-6 sha: 9932f54d23036a2cff36badbd6d1f29c5b6e4ab0 doc_id: 1033375 cord_uid: ehxxvenb nan cardiovascular disease through modulating ACE2 activation and expression to increase Ang 1-7 production and improve vascular function [17] . Owing to the role of ACE2 in the entry of SARS-CoV-2, the upregulated expression of ACE2 had an unwanted effect. Therefore, DIZE is not suggested to be applied in the treatment of SARS-CoV-2 infection. However, the addition of exogenous ACE2 could be a potential treatment for SARS-CoV-2 infection, which might not only restrain the spread of SARS-CoV-2 by blocking its interaction with ACE2 on the host cell, but also modulate RAS to treat SARS-CoV-2-related underlying comorbidities and protect the lung from developing ARDS. Given that ACE2 is generated mainly in Clara cells and type II alveolar epithelial cells, the production of ACE2 is severely impaired after epithelial injury in the development of ARDS [19] . In addition, the expression of ACE2 is also severely decreased in patients with pulmonary fibrosis [20] . Therefore, injection of recombinant human ACE2 (rhACE2) is currently considered for treating ARDS and pulmonary arterial hypertension [21] . Circulatory levels of ACE2 activity were markedly increased by rhACE2, which further effectively lowered Ang II levels and generated Ang 1-7 from Ang II (Fig. 1) . Although Ang II receptor and ACE blockage were also effective in lung failure in animal models, this treatment could cause potential adverse effects, causing systemic hypotension in humans [22] . As shown in Fig. 1 , rhACE2 also acts as a potential therapy for hypertension, heart failure, kidney injury, and liver fibrosis [22] [23] [24] . Currently, phase I (NCT00886353) and phase II (NCT01597635) clinical studies with a recombinant version of the catalytic ectodomain of human ACE2 (GSK2586881) have been successfully completed, providing safety and efficacy for ARDS treatment [25, 26] . The administration of rhACE2 was well tolerated without clinically significant hemodynamic changes in healthy subjects and patients with ARDS [26] . During the administration period, no antibodies to rhACE2 were detected, and no serious adverse events were reported [25] . The twice-daily doses of GSK2586881 treatment-regulated angiotensin system peptide, leading to a significant reduction in the concentration of Ang II, accompanied by a rapid rise in Ang 1-7 and Ang 1-5 concentrations, and caused a reduction in IL-6 concentration [26] . However, given the small cohort of critically ill patients, infusion of GSK2586881 did not contribute to ameliorated ARDS through physiological or clinical measures, and a clear role of GSK2586881 in the increased reports of adverse events referring to hypernatremia, pneumonia, dysphagia, and rash was difficult to establish. Therefore, to assess clinical outcomes powerfully, further clinical trials need a larger sample size. Recently, Monteil et al. [27] reported that hrACE2 could significantly inhibit SARS-CoV-2 infection of Vero-E6 cells, and of human capillary and kidney organoids, providing an evidence that rhACE2 might not only reduce lung injury but also block early entry of SARS-CoV-2 infections in target cells. Further studies are needed to illuminate the effect of hrACE2 in SARS-CoV-2 infections from bench to clinic. To ensure the quality of the data and clinical success of rhACE2, the trials for using rhACE2 in patients with SARS-CoV-2 infection or ARDS should consider the patient's stratification and continuous infusion dose. First, various plasma Ang II levels may pose some difficulties in identifying responders. Hence, before GSK2586881 infusion, the Ang II concentrations and the ratio of ACE2/ACE activity of enrolled patients were evaluated for improved risk stratification. ACE gene insertion/deletion (I/D) polymorphisms play an important role in the development of hypertension, nephritis, and cardiovascular diseases in different ethnic populations by influencing ACE and Ang II activities [28, 29] . Identifying the specific population that is most likely to benefit from rhACE2 represents a bright prospect. Second, due to the short half-life of soluble ACE2 in vivo, a continuous infusion of rhACE2 may enhance efficacy. In addition, an excess of rhACE2 is likely to influence the balance of the RAS; therefore, it is important to identify the effective infusion dose to prevent underlying RAS-related adverse events. Recently, it was reported that a chimeric fusion of rhACE2 and IgG2 Fc fragments could improve rhACE2 plasma stability [22] . This rhACE2-Fc fusion protein retained full peptidase activity and had extended plasma half-life in mice [24] . The strategy for rhACE2-Fc will be expected to provide patients with added convenience, largely reducing administration frequency and greatly improving treatment effectiveness [30] . Taken together, these findings indicate that rhACE2 would represent a potential therapeutic strategy for SARS-CoV-2 infection and its complications. Fig. 1 The mechanism and functions of rhACE2. rhACE2 is able to lower Ang II levels and increase Ang 1-7 levels effectively and exert protective effects in the heart, lung, liver, and kidney. A novel coronavirus from patients with pneumonia in China Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 A pneumonia outbreak associated with a new coronavirus of probable bat origin Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Structure of dimeric full-length human ACE2 in complex with B0AT1 SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically-proven protease inhibitor Ace revisited: a new target for structure-based drug design Angiotensin receptors ACE2, a promising therapeutic target for pulmonary hypertension Effects of losartan on haemodynamic parameters and angiotensin receptor mRNA levels in rat heart after myocardial infarction Time-dependent apoptotic development and pro-apoptotic genes expression in rat heart after myocardial infarction The angiotensin-converting enzyme gene family: genomics and pharmacology Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury Pathological findings of COVID-19 associated with acute respiratory distress syndrome The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents Angiotensin converting enzyme 2 is primarily epithelial and is developmentally regulated in the mouse lung Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis Recombinant human ACE2: acing out angiotensin II in ARDS therapy Recombinant human ACE2 and the angiotensin 1-7 axis as potential new therapies for heart failure ACE2 therapy using adeno-associated viral vector inhibits liver fibrosis in mice Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation Pharmacokinetics and pharmacodynamics of recombinant human angiotensinconverting enzyme 2 in healthy human subjects A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2 Association between genetic polymorphisms and angiotensin-converting enzyme inhibitor-induced cough: a systematic review and meta-analysis Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China